Cue Biopharma (STU:1UC) YoY EBITDA Growth : 15.73% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cue Biopharma YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Cue Biopharma's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 15.73%.

Cue Biopharma's EBITDA per Share for the three months ended in Mar. 2024 was €-0.21.

Cue Biopharma YoY EBITDA Growth Historical Data

The historical data trend for Cue Biopharma's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cue Biopharma YoY EBITDA Growth Chart

Cue Biopharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

11.35

12.06

4.34

-8.26

30.96

Cue Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
YoY EBITDA Growth	Get a 7-Day Free Trial															36.41	25.89	32.31	28.57	15.73

Cue Biopharma YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Cue Biopharma's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-0.923	-	-1.337)	/	\| -1.337 \|
=	30.96 %

Cue Biopharma's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2024 )
=	(EBITDA per Share (Q: Mar. 2024 )	-	EBITDA per Share (Q: Mar. 2023 ))	/	\| EBITDA per Share (Q: Mar. 2023 )) \|
=	(-0.209	-	-0.248)	/	\| -0.248 \|
=	15.73 %

Cue Biopharma YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Cue Biopharma's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Cue Biopharma (STU:1UC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cue Biopharma Inc (STU:1UC) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

CUE:USA

Address

40 Guest Street, Boston, MA, USA, 02135

Website

https://www.cuebiopharma.com

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401.

Cue Biopharma (STU:1UC) Headlines

No Headlines